Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.
Kodiak Sciences announced that its Phase 3 DAYBREAK study in wet age-related macular degeneration (wAMD) met its primary endpoints for both Zenkuda and tabirafusp-ted. Both drugs demonstrated non-inferiority in vision gains compared to aflibercept, with Zenkuda showing 6-month durability in 54% of patients. The company plans to submit a multi-indication Biologics License Application (BLA) for Zenkuda in the fourth quarter of 2026.
Lifecore Biomedical, Inc. \De\ Signs $664M M&A Deal with Webster Equity Partners
Lifecore Biomedical has entered into a definitive agreement to be acquired by Webster Equity Partners for up to $663.7 million. Common stockholders will receive $6.28 per share in cash at closing plus contingent value rights (CVRs) worth up to an additional $160 million in aggregate based on performance milestones. The transaction represents a 49.5% premium to the company's last closing price and will result in Lifecore becoming a privately held company.
Core Molding Technologies promoted Michael J. Gayford to Chief Operating Officer, effective immediately. Mr. Gayford, who joined the company in 2023 and previously served as Executive Vice President of Operations, will now oversee all North American operations and R&D initiatives. The promotion is part of the company's strategy to drive operational excellence and accelerate growth.
Quantum Corporation appointed James C. Clancy as Chief Operating Officer, effective September 28, 2026, following his resignation from the Board of Directors. His compensation package includes a $400,000 base salary, a 60% target bonus, 150,000 RSUs, and 400,000 stock options. The agreement also includes a change-of-control provision providing 12 months of salary and bonus plus full equity acceleration upon involuntary termination.
The Compensation Committee of Park Aerospace Corp. approved a significant increase in the annual base salary for Mark A. Esquivel, the company's President and Chief Operating Officer. His salary will increase from $270,000 to $400,000, effective September 28, 2026.
H.B. Fuller Company appointed R. Jeffrey Bailly, former CEO and current Executive Chairman of UFP Technologies, to its Board of Directors as a Class I director. Simultaneously, Ruth S. Kimmelshue resigned from the Board after nine years of service. Mr. Bailly will serve on the Audit and Compensation Committees and receive an annual cash retainer of $100,000 plus equity awards.
Silexion Therapeutics announced positive preclinical translational research findings for its lead RNAi candidate, SIL204, demonstrating a mechanism for systemic uptake in KRAS-driven cancers. The study showed that SIL204 utilizes native serum lipids and lipoprotein pathways for cellular entry and gene silencing without the need for artificial nanoparticles, supporting its upcoming Phase 2/3 clinical program.
Bitmine Immersion Technologies provided an operational update disclosing that its total crypto, cash, and marketable securities holdings have reached $17.2 billion. The company now holds over 6 million ETH tokens, representing approximately 4.9% of the total ETH supply, and reported that its institutional-grade staking platform MAVAN currently has 5,067,309 staked ETH.
Dynex Capital Chief Investment Officer Terrence John Connelly Jr. Buys $27.9K of Stock
Terrence John Connelly Jr., Chief Investment Officer, bought 2,500 shares of Dynex Capital Inc at $11.18 a share, worth $27.9K in total on Sep 25, 2026. Shares held after the trade: 58,695 (+4.4%).
Anixa Biosciences CEO Amit Kumar Buys $19.5K of Stock
Amit Kumar, CEO, bought 7,000 shares of Anixa Biosciences Inc at $2.78 a share, worth $19.5K in total on Sep 24, 2026. Shares held after the trade: 672,000 (+1.1%).
Greenland Energy Company successfully completed its 2026 environmental baseline field program at the Jameson Land Project in East Greenland. The program, which included soil sampling and wildlife studies, is a required regulatory step to support the Environmental Impact Assessment (EIA) and permitting process for future exploration drilling.
Burke & Herbert Financial Services Investor Presentation
Burke & Herbert Financial Services Corp. filed a formal fixed income investor presentation to be used in meetings with potential purchasers of its proposed Fixed-to-Floating Rate Subordinated Notes due 2036. The presentation provides strategic and financial updates following the company's merger with LINKBANCORP, Inc.
Silicon Valley Acquisition M&A Deal with EigenQ, Inc.
Silicon Valley Acquisition Corp. (SVAQ) entered into a third amendment to its definitive business combination agreement with EigenQ, Inc. The amendment modifies the treatment of certain EigenQ warrants, clarifying they will be exchanged for PubCo warrants upon the closing of the merger. This filing provides a status update on the pending SPAC merger which will result in EigenQ becoming a wholly owned subsidiary of the domesticated Delaware corporation.
Graphic Packaging Holding Company filed its Fall 2026 Corporate Governance and Stewardship presentation to be used in meetings with investors. The presentation provides a company overview, highlighting its global leadership in sustainable consumer packaging with $8.6 billion in 2025 net sales and over 100 facilities worldwide.
Chirantan “CJ” Desai has resigned as President and CEO of MongoDB to pursue a senior role at Meta Platforms, Inc. The Board has appointed former CEO Dev Ittycheria as Interim President and CEO while it initiates a search for a permanent successor. The company also reaffirmed its previously issued financial guidance for Q3 and full year fiscal 2027.
Anixa Biosciences Insider Arnold M. Baskies Buys $13.8K of Stock
Arnold M. Baskies bought 5,000 shares of Anixa Biosciences Inc at $2.76 a share, worth $13.8K in total on Sep 24, 2026. Shares held after the trade: 140,572 (+3.7%).
DeFi Development Corp. reported a 2% weekly increase in its Solana (SOL) treasury holdings, reaching a total of 2,538,010 SOL and SOL equivalents valued at approximately $309 million. The company has grown its SOL treasury by 10% since its August 12 earnings update and intends to deploy these assets through staking and validator infrastructure to support its 'Digital Credit 2.0' strategy.
Paramount Skydance Corporation announced a massive $44.4 billion offering of senior secured first and second lien notes to finance its pending acquisition of Warner Bros. Discovery. The debt package includes both U.S. dollar and euro-denominated notes and is intended to fund the purchase price and repay existing debt. The offering is part of a broader permanent financing plan that includes previously announced term loans and equity financing.
Cycurion, Inc. has terminated its Equity Purchase Agreement with Yield Point NY LLC for convenience, effective September 26, 2026. The company also provided a business update forecasting $843,028 in 2026 revenue from public safety engagements in Chicago and noted it is still awaiting a final delisting decision from the Nasdaq Hearings Panel.
Bold Eagle Acquisition Signs $1.25B M&A Deal with REDLattice
Bold Eagle Acquisition Corp. (BEAG) has entered into a definitive business combination agreement to acquire REDLattice, a cyber intelligence platform for defense and national security, at a pre-money enterprise value of $1.25 billion. The transaction is supported by $335 million in committed capital, including a $60 million common stock investment, and will result in REDLattice becoming a publicly traded company on the Nasdaq under the ticker 'REDL'.
TransCode Therapeutics announced updated Phase 1a clinical trial data for TTX-MC138, showing a 71.4% stable disease rate in patients with advanced solid tumors. The study met its primary safety endpoint with no dose-limiting toxicities reported, and three patients remained progression-free at the one-year mark. The company believes the durability of disease control warrants continued clinical evaluation of the RNA-based therapeutic candidate.
Adicet Bio announced positive preliminary Phase 1 data for prula-cel in patients with systemic lupus erythematosus (SLE) and lupus nephritis (LN), showing a 50% complete renal response rate and 54% DORIS remission at 12 months. The therapy was generally well tolerated with no Grade 3 or higher CRS and no ICANS, supporting potential outpatient administration. Based on these results, the company plans to initiate pivotal trial start-up activities in the fourth quarter of 2026.
Fate Therapeutics was awarded a $15 million CLIN2 grant from the California Institute for Regenerative Medicine (CIRM) to support its Phase 2 RECLAIM-LN clinical trial. The funding will advance the development of FT819, an off-the-shelf CAR T-cell therapy for patients with refractory lupus nephritis, a severe manifestation of systemic lupus erythematosus.
Counterparty
California Institute for Regenerative Medicine (CIRM)
Volato Group Wins $1.17B Contract from a large AI customer
Volato Group's subsidiary, Alignment Engine, signed a Master Services Agreement and two initial orders with a large AI customer for dedicated AMD GPU infrastructure in Ohio. The aggregate contract value is approximately $1.17 billion over a four-year take-or-pay term, including $133 million in contractual prepayments. This represents a transformational milestone for the company's AI infrastructure platform.
4D Molecular Therapeutics announced the enrollment of the first patients in its 4SIGHT Phase 3 clinical trial evaluating 4D-150 for diabetic macular edema (DME). The company also released positive 2-year data from its SPECTRA clinical trial, showing 4D-150 was well tolerated with a 61% reduction in treatment burden compared to standard aflibercept injections.
BGC Group reaffirmed its previously stated financial outlook for the third quarter ending September 30, 2026. The company maintained its existing ranges for both revenue and pre-tax Adjusted Earnings as originally issued on July 30, 2026.
The FDA has approved Mirum Pharmaceuticals' Atebrioz (zilurgisertib) for the treatment of fibrodysplasia ossificans progressiva (FOP) in patients aged 12 and older. The drug, licensed from Incyte, is a first-of-its-kind oral ALK2 inhibitor designed to reduce new heterotopic ossification (abnormal bone formation). Mirum expects the product to be commercially available in the U.S. in October 2026.
Ainos Licensing Deal with BioPhoenix Co., Ltd. Worth $10M
Ainos entered into a global exclusive license agreement with BioPhoenix for its VELDONA low-dose oral interferon alpha technology platform for Sjögren’s Disease and Thrombocytopenia. Ainos will receive an upfront fee of $600,000 and is eligible for up to $10.0 million in total fees if additional indications are licensed, plus 25% of net sublicensing revenue. BioPhoenix will assume all clinical and regulatory funding and execution for the licensed indications.
Keros Therapeutics announced the dosing of the first patient in its Phase 2 clinical trial evaluating rinvatercept for the treatment of Duchenne muscular dystrophy (DMD). The open-label, multi-cohort trial will assess safety, tolerability, and functional improvements in ambulatory and non-ambulatory patients, with initial data expected in the first half of 2027.
SHF Holdings (Safe Harbor Financial) has approved a 1-for-12 reverse stock split of its common stock, effective September 30, 2026. The split aims to consolidate every twelve outstanding shares into one share to adjust the trading price on the Nasdaq Stock Market. Stockholders previously approved the measure at a special meeting held in November 2025.